Review presentations and publications from around the globe.

Our work in nucleic acid therapeutics has been received well by the scientific community. Here are approximately 30 recent presentations and publications that review the advances we’ve made in nucleic acid therapeutics.



European Society for Medical Oncology 2017 Congress

Third Annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz, Germany, September 6-9, 2017

AACR 2017 Annual Meeting, Washington, DC, April 1-5, 2017


OPT Boston 2017, Cambridge, MA, March 27-29, 2017


2017 ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, February 23-25, 2017


SITC 2016 Annual Meeting, National Harbor, MD, November 9-13, 2016


AACR 2016 Annual Meeting, New Orleans, LA, April 16-20, 2016


ASH 57th Annual Meeting & Exposition, Orlando, FL, December 5–8, 2015


AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5-9, 2015


CRI-CIMT-EATI-AACR – The Inaugural International Cancer Immunotherapy Conference, New York, NY, September 16–19, 2015


ASH 56th Annual Meeting & Exposition, San Francisco, CA, December 6–9, 2014


ASH Meeting on Lymphoma Biology, Colorado Springs, CO, August 10–13, 2014


AACR Annual Meeting, San Diego, CA, April 5–9, 2014

Rare Diseases

Brevard et al., Design Considerations for Clinical Trials Using the Cutaneous Dermatomyositis Disease Area and Severity Index as a Primary Endpoint. J Clin Exp Dermatol Res 2017, 8:4.


GCOM (Global Conference on Myositis), Potomac, MD, May 5-8, 2017


MDA Scientific Conference 2017, Arlington, VA, March 19-22, 2017


MDA Scientific Conference 2015, Washington, DC, March 11–14, 2015


8th International Workshop on Waldenström’s Macroglobulinemia and Symposium on Advances in Multiple Myeloma, London, U.K., August 13–17, 2014

Third-Generation Antisense

OPT Boston 2017, Cambridge, MA, March 27-29, 2017

The 12th Annual Meeting of the Oligonucleotide Therapeutics Society, Montreal, Quebec, September 25 – 28, 2016

Cold Spring Harbor Laboratory Conference on Regulatory & Non-Coding RNAs, Cold Spring Harbor, NY, August 23 – 27, 2016


Bhagat L, Putta MR, Wang D, Yu D, Lan T, Jiang W, Sun Z, Wang H, Tang JX, La Monica N, Kandimalla ER, Agrawal S. Novel oligonucleotides containing two 3′-ends complementary to target mRNA show optimal gene-silencing activity. J Med Chem. 2011 Apr 28;54(8):3027–36.


Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem. 2009 Aug 27;52(16):5108–14.

Toll-Like Receptors


AAD Annual Meeting, San Francisco, CA, March 20–24, 2015


Digestive Disease Week, Washington DC, May 16–19, 2015


10th Annual Meeting of the Oligonucleotide Therapeutics Society, San Diego, CA, October 12–15, 2014


AACR Tumor Immunology and Immunotherapy Meeting, Orlando, FL, December 1–4, 2014


ACR/ARHP Annual Meeting, San Diego, CA, October 25–30, 2013


FOCIS 2013, Cambridge, MA, June 27–30, 2013


International Investigative Dermatology, Edinburgh, Scotland, May 8–11, 2013


AAD Annual Meeting, Miami Beach, FL, March 1–5, 2013


ACR/ARHP Annual Meeting, Washington, DC, November 9–14, 2012


Immunology 2012 AAI Conference, Boston, MA, May 4–8, 2012


Suárez-Fariñas M, Arbeit R, Jiang W, Ortenzio FS, Sullivan T, Krueger JG. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS ONE. 2013 Dec 27;8(12):e84634.


Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N, Agrawal S. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 2013 Apr 1;41(6):3947–61.


Jiang W, Zhu FG, Bhagat L, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol. 2013 Jul;133(7):1777–84.


Zhu FG, Jiang W, Bhagat L, Wang D, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity. 2013 Nov;46(7):419–28.


Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem. 2009 Jan 22;52(2):551–8.


Yu D, Zhao Q, Kandimalla ER, Agrawal S. Accessible 5′-end of CpG-containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity. Bioorg Med Chem Lett. 2000 Jul;10:2585–8.

  • Our Approach

    Learn more about our unwavering dedication to defeating certain cancers and rare diseases.